Reflection on clinical and methodological issues in rare disease clinical trials

Experts provide a comprehensive reflection on the unique clinical and methodological challenges inherent in designing and executing trials for rare diseases.

This paper discusses the specific hurdles faced in rare disease research, including small patient populations and recruitment difficulties. It reflects on innovative trial designs and statistical methods that can enhance the robustness of clinical evidence in these settings.

Acces this publication
orphanet

Source

Orphanet Journal of Rare Diseases

You might also be interested in

Cover of the 16-country rare disease policy assessment, October 2026.

Reckoning With the Rare Disease Landscape. A 16 Country Policy Landscape Assessment across the Life Course.

The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.
Genetic Mapping

New clinical trial guidance supports research beyond the hospital

New international guidance supports decentralised clinical trials, pragmatic designs and the use of real-world data.
ERDERA - World Orphan Drug Congress - JVDPhotography-40

Can AI deliver for rare diseases? ERDERA brings the debate to WODC Europe

ERDERA will return to the World Orphan Drug Congress Europe with a booth and an interactive pre-conference workshop examining where artificial intelligence can support rare disease research and therapeutic development, and where human expertise remains essential.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Annex IV. Guidelines for Canadian Applicants

This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.

ERDERA Search